<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7404079\results\search\disease\results.xml">
  <result pre="10.1186/s13148-020-00912-7 : Review Management of epigenomic networks entailed in coronavirus" exact="infections" post="and COVID-19 El BabaRanimranim.elbaba@live.com12http://orcid.org/0000-0002-7993-0221HerbeinGeorgesgeorges.herbein@univ-fcomte.fr13[1], grid.7459.f0000 0001 2188 3779Department Pathogens"/>
  <result pre="(CoVs) are highly diverse single-stranded RNA viruses owing to their" exact="susceptibility to" post="numerous genomic mutations and recombination. Such viruses involve human"/>
  <result pre="involve human and animal pathogens including the etiologic agents of" exact="acute" post="respiratory tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV),"/>
  <result pre="human and animal pathogens including the etiologic agents of acute" exact="respiratory" post="tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle"/>
  <result pre="including the etiologic agents of acute respiratory tract illnesses: severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus"/>
  <result pre="the etiologic agents of acute respiratory tract illnesses: severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV),"/>
  <result pre="etiologic agents of acute respiratory tract illnesses: severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and"/>
  <result pre="tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus"/>
  <result pre="illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus disease"/>
  <result pre="respiratory syndrome coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus" exact="disease" post="2019 (COVID-19), an emerging disease with a quick rise"/>
  <result pre="the highly morbific SARS-CoV-2. Coronavirus disease 2019 (COVID-19), an emerging" exact="disease" post="with a quick rise in infected cases and deaths,"/>
  <result pre="and deaths, was recently identified causing a worldwide pandemic. COVID-19" exact="disease" post="outcomes were found to increase in elderly and patients"/>
  <result pre="deaths is the cytokine storm, which is illustrated by an" exact="uncontrolled" post="over-production of soluble markers of inflammation. The regulation process"/>
  <result pre="coronavirus pathogenesis through molecular mechanism comprise virus-host interactions linked to" exact="viral" post="entry, replication and transcription, escape, and immune system control."/>
  <result pre="replication and transcription, escape, and immune system control. Recognizing coronavirus" exact="infections" post="and COVID-19 through epigenetics lens will lead to potential"/>
  <result pre="drugs is currently considered an effective and valuable approach for" exact="viral" post="replication and inflammatory overdrive control. Keywords Coronavirus SARS-CoV MERS-CoV"/>
  <result pre="in February, 2003 [9, 10]. It resulted in 8098 human" exact="infections" post="and 774 deaths, and it disseminated into 37 countries"/>
  <result pre="countries [3, 12]. While the MERS-CoV outbreak has been mostly" exact="limited" post="to the Middle Eastern region, it is likely that"/>
  <result pre="in American, European, Eastern Mediterranean, Western Pacific, South-East Asia, and" exact="African" post="regions [15]. However, underestimating COVID-19â€™s burden was due to"/>
  <result pre="by the Food and Drug Administration (FDA) has remained relatively" exact="limited" post="[11, 16]. Generally, the available treatment strategies for emerging"/>
  <result pre="the development of antiviral therapeutics and vaccines [9, 18]. The" exact="primary" post="objective of this review is to evaluate the epigenetic"/>
  <result pre="review is to evaluate the epigenetic mechanisms involved in HCoVsâ€™" exact="infection" post="and to highlight on epigenetic therapies in order to"/>
  <result pre="in the SARS-CoV-2 genome [11, 19]. SARS-CoV-2 genome encodes for" exact="viral" post="proteins involved in viral replication named non-structural proteins (Nsp)"/>
  <result pre="[11, 19]. SARS-CoV-2 genome encodes for viral proteins involved in" exact="viral" post="replication named non-structural proteins (Nsp) including the replicase complex"/>
  <result pre="(Nsp) including the replicase complex coded by ORF1ab, and structural" exact="viral" post="proteins involved in viral assembly including the spike (S),"/>
  <result pre="complex coded by ORF1ab, and structural viral proteins involved in" exact="viral" post="assembly including the spike (S), envelope (E), membrane (M),"/>
  <result pre="a class I fusion glycoprotein, forms homotrimers bulging in the" exact="viral" post="surface facilitating the viral envelope binding to host cells"/>
  <result pre="glycoprotein, forms homotrimers bulging in the viral surface facilitating the" exact="viral" post="envelope binding to host cells by attraction with angiotensin-converting"/>
  <result pre="Hence, disparities in the S protein would directly impact the" exact="viral" post="biological characteristics including pathogenicity and antigenicity. Spike protein has"/>
  <result pre="HMTi). Inhibiting some epigenetic targets leads to a decrease in" exact="viral" post="replication load; thus, acting as a vital therapeutic strategy"/>
  <result pre="of COVID-19 [11, 21]. ACE2 is significantly expressed in the" exact="lower" post="respiratory tract such as type II alveolar cells (AT2)"/>
  <result pre="COVID-19 [11, 21]. ACE2 is significantly expressed in the lower" exact="respiratory" post="tract such as type II alveolar cells (AT2) of"/>
  <result pre="is significantly expressed in the lower respiratory tract such as" exact="type II" post="alveolar cells (AT2) of the lungs, upper esophagus, and"/>
  <result pre="such as type II alveolar cells (AT2) of the lungs," exact="upper" post="esophagus, and stratified epithelial cells, as well as in"/>
  <result pre="alveolar cells (AT2) of the lungs, upper esophagus, and stratified" exact="epithelial" post="cells, as well as in kidney proximal tubule cells,"/>
  <result pre="and cholangiocytes. Such cellular outspreading elucidates the consequences of SARS-CoV-2" exact="infection" post="that is not only limited to respiratory disorders but"/>
  <result pre="elucidates the consequences of SARS-CoV-2 infection that is not only" exact="limited" post="to respiratory disorders but also to kidney, liver, heart,"/>
  <result pre="consequences of SARS-CoV-2 infection that is not only limited to" exact="respiratory" post="disorders but also to kidney, liver, heart, and gastrointestinal"/>
  <result pre="axis parallel to the downregulation of the Angiotensin II receptor" exact="type 1" post="(AT1R) expression belonging to the prorenin receptor (PRR)/ACE/angiotensin II"/>
  <result pre="probably due to decreased hyperinflammation [28â€&quot;30]. Similarly, SIRT1 could impact" exact="viral" post="entry of SARS-CoV and HCoV-NL63 which also use ACE2"/>
  <result pre="entry of SARS-CoV and HCoV-NL63 which also use ACE2 for" exact="viral" post="entry [31]. Foremost host cellular receptors significantly utilized by"/>
  <result pre="cellular receptors significantly utilized by other HCoVs for entry and" exact="viral" post="replication are aminopeptidase N (APN) by HCoV-229E, dipeptidyl peptidase"/>
  <result pre="expression and azacitidine (5-azaC) induces APN protein expression [34]. In" exact="melanoma" post="cells, the combination of HDAC inhibitor CHR-3996 and APN"/>
  <result pre="The RdRp, also known as Nsp12, catalyzes the synthesis of" exact="viral" post="RNA and thus plays a central role in the"/>
  <result pre="critical for the replication of several viruses including herpesviruses, human" exact="immunodeficiency" post="viruses (HIV), human T-lymphotropic virus (HTLV), human adenovirus (HAdV),"/>
  <result pre="T-lymphotropic virus (HTLV), human adenovirus (HAdV), influenza A virus and" exact="Dengue" post="virus (DENV) [38]. The interaction between Nsp7 and P-TEFb"/>
  <result pre="and have been reported to be latency reversal agents in" exact="HIV infection" post="[39]. Nsp14, a 3â€²-5â€² exonuclease, is critical for coronavirus"/>
  <result pre="have been reported to be latency reversal agents in HIV" exact="infection" post="[39]. Nsp14, a 3â€²-5â€² exonuclease, is critical for coronavirus"/>
  <result pre="of newly synthesized RNA strand and thus the production of" exact="infectious" post="viral particles [43]. Since p300 expression is under HDACsâ€™"/>
  <result pre="newly synthesized RNA strand and thus the production of infectious" exact="viral" post="particles [43]. Since p300 expression is under HDACsâ€™ control"/>
  <result pre="with coronavirus replication. The Nsp3-Nsp4-Nsp6 complex is also involved in" exact="viral" post="replication. Remarkably, Nsp4 interacts with HDAC2, and this could"/>
  <result pre="the 3â€² non-translated region of the SARS virus [47]. Most" exact="recurrent" post="transcription regulating sequence (TRS) related to MERS-CoV is TRS2."/>
  <result pre="AP12 [48]. Epigenetic regulation of HCoV protein maturation Newly synthesized" exact="viral" post="polyproteins are cleaved by viral proteases, namely, the 3C-like"/>
  <result pre="HCoV protein maturation Newly synthesized viral polyproteins are cleaved by" exact="viral" post="proteases, namely, the 3C-like protease (3CLpro) and the papain-like"/>
  <result pre="of its polyprotein, 3CLpro is responsible for cleavage of the" exact="residual" post="11 locations resulting in release of a total of"/>
  <result pre="of the residual 11 locations resulting in release of a" exact="total" post="of 16 Nsp in both SARS-CoV and MERS-CoV [45]."/>
  <result pre="[45]. Thus, 3CLpro mimics HDAC2 inhibitor and might therefore facilitate" exact="viral" post="and/or cellular gene expression in infected cells. TRMT1-catalyzed tRNA"/>
  <result pre="of 3CLpro including the anti-HIV drug lopinavir [16]. The structural" exact="viral" post="proteins (NP, M, E, and S) participate in the"/>
  <result pre="treatment of the infected cells with resveratrol results in decreased" exact="viral" post="replication [51]. The viral envelope E binds to BRD2"/>
  <result pre="cells with resveratrol results in decreased viral replication [51]. The" exact="viral" post="envelope E binds to BRD2 and BRD4 and could"/>
  <result pre="from the usage of SARS-CoV-2 protease inhibitors to annihilate the" exact="viral" post="polyprotein cleavage by 3CL pro and/or PLpro, and secondly"/>
  <result pre="epigenetic treatments to decrease the amount and/or activity of structural" exact="viral" post="proteins. Epigenetic-targeted therapies controlling coronavirus replication Understanding fundamental elements"/>
  <result pre="elements of epigenetic regulation is progressively contributing to concepts of" exact="viral" post="epigenetic therapeutics. Epigenetic therapies are among the most active"/>
  <result pre="epidrugs could be associated with a risk generating from the" exact="systemic" post="effect of such therapies. Yet, knowing that HCoVs including"/>
  <result pre="proposed epigenetic treatments can be site-directed and consequently minimize unwanted" exact="systemic" post="risk. Furthermore, it is imperative to spotlight the SARS-CoV-2"/>
  <result pre="the SARS-CoV-2 direct RNA sequence data including RNA modifications, the" exact="viral" post="transcriptome and epitranscriptome as it could anticipate novel-targeted strategies"/>
  <result pre="it could anticipate novel-targeted strategies for the management of SARS-CoV-2" exact="infection" post="[52]. Antiviral therapies targeting the pathogen itself act by"/>
  <result pre="targeting the pathogen itself act by inhibiting enzymes responsible for" exact="viral" post="genome replication, the viral assembly process, and preventing viral"/>
  <result pre="act by inhibiting enzymes responsible for viral genome replication, the" exact="viral" post="assembly process, and preventing viral entry by blocking the"/>
  <result pre="for viral genome replication, the viral assembly process, and preventing" exact="viral" post="entry by blocking the virus-host receptor binding. Remdesivir, favipiravir,"/>
  <result pre="its salt form (BCX-4430) targeting RdRp; ritonavir and darunavir targeting" exact="viral" post="proteases (3CLpro or PLpro) in addition to camostat mesylate"/>
  <result pre="possesses an antiviral and an anti-inflammatory effect [16]. In the" exact="primary" post="stages of SARS-CoV epidemic, an empirical treatment of broad"/>
  <result pre="healthcare community struggling to cope during an outbreak of emerging" exact="viral" post="infections (Table 1). Histone deacetylases (HDACs) resemble a main"/>
  <result pre="community struggling to cope during an outbreak of emerging viral" exact="infections" post="(Table 1). Histone deacetylases (HDACs) resemble a main epigenetic"/>
  <result pre="(HDACs) resemble a main epigenetic target for the treatment of" exact="viral" post="infections [64, 65] (Fig. 1b). Hence, HDACs class III"/>
  <result pre="resemble a main epigenetic target for the treatment of viral" exact="infections" post="[64, 65] (Fig. 1b). Hence, HDACs class III such"/>
  <result pre="(SREBP-1), and DNA methyltransferase (DNMT)1 thus targeting the regulation of" exact="viral infection" post="[22, 57]. Significant downregulation of apoptosis induced by MERS-CoV,"/>
  <result pre="and DNA methyltransferase (DNMT)1 thus targeting the regulation of viral" exact="infection" post="[22, 57]. Significant downregulation of apoptosis induced by MERS-CoV,"/>
  <result pre="by MERS-CoV, prolonged cellular survival post-MERS-CoV infection, potential decrease in" exact="viral" post="NP protein expression, and decreased viral replication were detected"/>
  <result pre="infection, potential decrease in viral NP protein expression, and decreased" exact="viral" post="replication were detected after resveratrol administration [51]. Besides HDACs"/>
  <result pre="for the treatment of several cancers such as T cell" exact="lymphoma" post="and relapse of multiple myeloma [68â€&quot;70]. Knowing that viruses"/>
  <result pre="several cancers such as T cell lymphoma and relapse of" exact="multiple myeloma" post="[68â€&quot;70]. Knowing that viruses depend on hostâ€™s epigenetic machinery,"/>
  <result pre="cancers such as T cell lymphoma and relapse of multiple" exact="myeloma" post="[68â€&quot;70]. Knowing that viruses depend on hostâ€™s epigenetic machinery,"/>
  <result pre="depend on hostâ€™s epigenetic machinery, some epigenetic drugs used in" exact="cancer" post="therapies were shown to give a potential broad spectrum"/>
  <result pre="have the ability to attain cellular antiviral state and reduce" exact="viral" post="yields instead of inducing activation [68, 71]. A pan-HKMT"/>
  <result pre="DNA viruses by boosting a potential innate immune response, blocking" exact="viral" post="attachment, inducting DNA damage response (DDR), decreasing viral replication,"/>
  <result pre="response, blocking viral attachment, inducting DNA damage response (DDR), decreasing" exact="viral" post="replication, and arresting cell-cycle with no apoptotic signs. Bromodomain"/>
  <result pre="replication of SARS-CoV-2 genome [45, 75]. JQ-1 exhibited a potential" exact="viral" post="inhibition at low doses; dBET6 expressed lower cytotoxicity levels"/>
  <result pre="exhibited a potential viral inhibition at low doses; dBET6 expressed" exact="lower" post="cytotoxicity levels than JQ-1. Knowing that the bromodomain and"/>
  <result pre="prior patient use [45]. Table 1 Epigenetics involved in coronavirus" exact="infection" post="and their therapeutic control Epigenetic drug target Antagonism â€œinhibitorsâ€�"/>
  <result pre="ribavirin, favipiravir, galidesivir) or (rapamycin, selumetinib, trametinib) or prostatin TSA" exact="Reduced" post="pro-inflammatory mediatorâ€™s production and increased IL-10 production [55]. TSA"/>
  <result pre="replication, and induced the expression of cellular proteins responsible for" exact="viral" post="inhibition [57]. SAHA + antivirals or (rapamycin, selumetinib, trametinib)"/>
  <result pre="HKMT Pan-HKMT EZH2 DZNep Attained cellular antiviral state and reduced" exact="viral" post="yields [57]. DZNep + vorinostat HKMT G9a BIX-01294 Enhancing"/>
  <result pre="Enhancing antiviral state [57]. BIX-01294 + vorinostat HMT Suv39H1 Chaetocin" exact="Permanent" post="cell cycle arrest and RNA transcript blockage [59]. HAT"/>
  <result pre="Down-regulation of apoptosis, decrease in (N) protein expression, and RNA" exact="viral" post="replication antagonism [51]. Decitabine (5-azadC) Counteracting hyper-inflammation: lowering pro-inflammatory"/>
  <result pre="TGF-Î² [58]. 5-azadC + antivirals or (rapamycin, selumetinib, trametinib) Azacitidine" exact="Viral" post="mimicry [62]. Azacitidine + antivirals or (rapamycin, selumetinib, trametinib)"/>
  <result pre="RVX-208 BRD4 inhibition boosts a potential innate immune response, blocks" exact="viral" post="attachment, inducts DNA damage response (DDR), decreases viral replication,"/>
  <result pre="response, blocks viral attachment, inducts DNA damage response (DDR), decreases" exact="viral" post="replication, and arrests cell-cycle with no apoptotic signs [63]."/>
  <result pre="MZ1 Epigenetic regulation of cellular and immune landscape during coronavirus" exact="infection" post="Cellular and immune landscape during coronavirus infection In the"/>
  <result pre="landscape during coronavirus infection Cellular and immune landscape during coronavirus" exact="infection" post="In the course of viral infections, innate immune cells"/>
  <result pre="and immune landscape during coronavirus infection In the course of" exact="viral" post="infections, innate immune cells initiate a transcriptional signal that"/>
  <result pre="signal transducer and activator of transcription 1 (STAT1), myeloid differentiation" exact="primary" post="response gene 88 (MyD88), Toll-like receptor (TLR)4, TLR7, and"/>
  <result pre="Toll-like receptor (TLR)4, TLR7, and TLR3/TIR-domain-containing adapter-inducing interferon-beta (TRIF) diminish" exact="infection" post="severity during HCoV infection in vivo. Moreover, interferons (IFN-alpha,"/>
  <result pre="and TLR3/TIR-domain-containing adapter-inducing interferon-beta (TRIF) diminish infection severity during HCoV" exact="infection" post="in vivo. Moreover, interferons (IFN-alpha, IFN-beta, IFN-gamma) which are"/>
  <result pre="which are regulated by histone marks aid in controlling HCoV" exact="infections" post="in vivo and in vitro. IFN and tumor necrosis"/>
  <result pre="controlling HCoV infections in vivo and in vitro. IFN and" exact="tumor" post="necrosis factor (TNF) are the primary response genes of"/>
  <result pre="in vitro. IFN and tumor necrosis factor (TNF) are the" exact="primary" post="response genes of the innate immune system whose promoters"/>
  <result pre="undesired expression of compelling mediators, and repression or stimulation of" exact="secondary" post="gene programs [18]. Upon utilizing chromatin immuno-precipitation (ChIP) PCR"/>
  <result pre="open chromatin and promoting active transcription and ISG expression. MERS-CoV" exact="infection" post="of Calu3, a continuous human airway epithelial cell line,"/>
  <result pre="ISG expression. MERS-CoV infection of Calu3, a continuous human airway" exact="epithelial" post="cell line, resulted in increased levels of H3K27me3 and"/>
  <result pre="different in two close CoV members, namely SARS-CoV and MERS-CoV." exact="Acute respiratory distress syndrome" post="(ARDS) is a common immunopathological event for SARS-CoV, MERS-CoV,"/>
  <result pre="in two close CoV members, namely SARS-CoV and MERS-CoV. Acute" exact="respiratory" post="distress syndrome (ARDS) is a common immunopathological event for"/>
  <result pre="close CoV members, namely SARS-CoV and MERS-CoV. Acute respiratory distress" exact="syndrome" post="(ARDS) is a common immunopathological event for SARS-CoV, MERS-CoV,"/>
  <result pre="CXCL8, CXCL9, CXCL10) are upregulated by effector cells in SARS-CoV" exact="infection" post="linked with respiratory distress [14, 77â€&quot;79]. Unlike the proinflammatory"/>
  <result pre="are upregulated by effector cells in SARS-CoV infection linked with" exact="respiratory" post="distress [14, 77â€&quot;79]. Unlike the proinflammatory cytokine IL-6, the"/>
  <result pre="IFN-Î³-inducible protein 10 (IP10), macrophage inflammatory protein 1-Î± (MIP1A), and" exact="monocyte" post="chemoattractant protein (MCP1) were associated with COVID-19 severity; a"/>
  <result pre="(MCP1) were associated with COVID-19 severity; a cytokine outline favoring" exact="secondary" post="hemophagocytic lymphohistiocytosis (sHLH) [80, 81]. Poor prognosis of SARS-CoV-2"/>
  <result pre="were associated with COVID-19 severity; a cytokine outline favoring secondary" exact="hemophagocytic lymphohistiocytosis" post="(sHLH) [80, 81]. Poor prognosis of SARS-CoV-2 infected patients"/>
  <result pre="prognosis of SARS-CoV-2 infected patients can be forecasted by SARS-CoV-2" exact="viral" post="load which is concomitant with cytokine storm caused by"/>
  <result pre="lung of COVID-19 patients can also be shaped by SARS-CoV-2" exact="infection" post="of the airway epithelial cells. Thus, prominent epigenetic regulators"/>
  <result pre="can also be shaped by SARS-CoV-2 infection of the airway" exact="epithelial" post="cells. Thus, prominent epigenetic regulators including HDAC2 and BRDs"/>
  <result pre="epigenetic regulators including HDAC2 and BRDs (BRD2, BRD4) interact with" exact="viral" post="proteins Nsp5 and E, respectively. Nsp5 antagonizes HDAC2 transport"/>
  <result pre="patients result from epigenetic modifications present in both HCoV infected" exact="epithelial" post="cells and immune cells present in their vicinity. Epigenetic"/>
  <result pre="Targeted anti-cytokine methodologies have proven efficacious in handling cytokine storm" exact="syndrome" post="[77]. Dexamethasone, an effectual corticosteroid, was shown recently to"/>
  <result pre="effectual corticosteroid, was shown recently to decrease the cytokine storm" exact="syndrome" post="with reduced mortality rates in COVID19 patients [84, 85]."/>
  <result pre="proved a remarkable survival benefit in patients experiencing hyperinflammation post-SARS-CoV-2" exact="infection" post="[80, 81]. IFN-Î±Î² and IFN-Î³ inhibitors mitigate HCoV-induced inflammation;"/>
  <result pre="therapy must be taken into consideration as it defines the" exact="disease" post="outcome. An early IFN response was protective in SARS-CoV-infected"/>
  <result pre="of SARS-CoV, IFN-Î±Î² receptor antagonists prevent inflammatory responses; IFNÎ³ neutralization" exact="limited" post="IFN-Î± production [78, 79]. Supplementary, anti-TNFÎ± antibody administration significantly"/>
  <result pre="was curbed [64, 76]. Fig. 2 Epigenetics in COVID-19 immune" exact="syndrome" post="and targeted therapies. Cytokine storm occurred in the majority"/>
  <result pre="occurred in the majority of severe COVID-19 cases; hypercytokinemia post-coronavirus" exact="infections" post="can be harmful and sometimes deadly. Activated immune cells"/>
  <result pre="patients associated with poor prognosis. Combination therapy to fight coronavirus" exact="infections" post="including antiviral and epigenetic drugs Suitable combination therapies reduce"/>
  <result pre="Suitable combination therapies reduce the likelihood of drug resistance, suppress" exact="viral" post="replication, lower toxicity levels, and provide synergistic effects (Table"/>
  <result pre="therapies reduce the likelihood of drug resistance, suppress viral replication," exact="lower" post="toxicity levels, and provide synergistic effects (Table 1). Achieving"/>
  <result pre="few therapeutic combinations have been evaluated to cope with this" exact="viral" post="outbreak. Some patients were clinically recovered after the administration"/>
  <result pre="to the control groups, confirmed SARS-CoV cases undergo a milder" exact="disease" post="progression with no consequences. In another retrospective analysis, patients"/>
  <result pre="Jeddah was treated with oral lopinavir/ritonavir, pegylated IFN, and ribavirin." exact="Viral" post="RNA was detected in feces, serum, and respiratory secretionsâ€™"/>
  <result pre="and ribavirin. Viral RNA was detected in feces, serum, and" exact="respiratory" post="secretionsâ€™ samples after 2 days for initiating the therapy"/>
  <result pre="of NP protein in addition to SIRT-1 activation which counteracts" exact="viral" post="replication and hyperinflammation [51]. The anti-viral and anti-inflammatory effects"/>
  <result pre="as it operated at entry and post-entry phases of SARS-CoV-2" exact="infection" post="[16, 96â€&quot;98]. Generally, CQ blocks viral infection by elevating"/>
  <result pre="post-entry phases of SARS-CoV-2 infection [16, 96â€&quot;98]. Generally, CQ blocks" exact="viral infection" post="by elevating endosomal pH necessary for entry, replication, and"/>
  <result pre="phases of SARS-CoV-2 infection [16, 96â€&quot;98]. Generally, CQ blocks viral" exact="infection" post="by elevating endosomal pH necessary for entry, replication, and"/>
  <result pre="prevention [99]. Conclusion and perspectives Providing more research to generate" exact="infection" post="control therapeutic interventions is a major challenge. The three"/>
  <result pre="coronavirus global outbreaks emphasized the exigent need for curtailing CoVs" exact="infections" post="despite the presence of many therapeutic options including epigenetic"/>
  <result pre="still in progress [14, 89]. Live attenuated and deactivated virus," exact="viral" post="vectors, recombinant DNA, subunit, and protein vaccines are considered"/>
  <result pre="kinase 1 ACE Angiotensin-converting enzyme ACE2 Angiotensin-converting enzyme 2 ALI" exact="Acute" post="lung injury AMPK 5' AMP-activated protein kinase Ang II"/>
  <result pre="Accessory proteins AP-1 Activator protein 1 APN Aminopeptidase N ARDS" exact="Acute respiratory distress syndrome" post="AT1R Angiotensin II receptor type 1 AT2 Type II"/>
  <result pre="proteins AP-1 Activator protein 1 APN Aminopeptidase N ARDS Acute" exact="respiratory" post="distress syndrome AT1R Angiotensin II receptor type 1 AT2"/>
  <result pre="Activator protein 1 APN Aminopeptidase N ARDS Acute respiratory distress" exact="syndrome" post="AT1R Angiotensin II receptor type 1 AT2 Type II"/>
  <result pre="N ARDS Acute respiratory distress syndrome AT1R Angiotensin II receptor" exact="type 1" post="AT2 Type II alveolar cells BET Bromodomain and extra-terminal"/>
  <result pre="respiratory distress syndrome AT1R Angiotensin II receptor type 1 AT2" exact="Type II" post="alveolar cells BET Bromodomain and extra-terminal motif BRD Bromodomain-containing"/>
  <result pre="BRD Bromodomain-containing protein CCL/CXCL Chemokine ChIP Chromatin immuno-precipitation COVID-19 Coronavirus" exact="infectious disease" post="2019 CoVs Coronaviruses CQ Chloroquine DCs Dendritic cells DDR"/>
  <result pre="Bromodomain-containing protein CCL/CXCL Chemokine ChIP Chromatin immuno-precipitation COVID-19 Coronavirus infectious" exact="disease" post="2019 CoVs Coronaviruses CQ Chloroquine DCs Dendritic cells DDR"/>
  <result pre="CQ Chloroquine DCs Dendritic cells DDR DNA damage response DENV" exact="Dengue" post="virus DNMT DNA methyltransferase DPP4 Dipeptidyl peptidase 4 DZNep"/>
  <result pre="acetyltransferase inhibitors HCoVs Human coronaviruses HDAC Histone deacetylase HIV Human" exact="immunodeficiency" post="viruses HMT Histone methyltransferases HPV Human papilloma virus HTLV"/>
  <result pre="deacetylase HIV Human immunodeficiency viruses HMT Histone methyltransferases HPV Human" exact="papilloma" post="virus HTLV Human T-lymphotropic virus HXIM1 Hexamethylene bisacetamide inducible"/>
  <result pre="gene LARP7 La-related protein M Membrane MasR Mas receptor MCP1" exact="Monocyte" post="chemoattractant protein MEPCE Methyl-phosphate capping enzyme MERS-CoV Middle East"/>
  <result pre="Monocyte chemoattractant protein MEPCE Methyl-phosphate capping enzyme MERS-CoV Middle East" exact="respiratory" post="syndrome coronavirus MIP1A Macrophage inflammatory protein 1-Î± MNA Microneedle"/>
  <result pre="chemoattractant protein MEPCE Methyl-phosphate capping enzyme MERS-CoV Middle East respiratory" exact="syndrome" post="coronavirus MIP1A Macrophage inflammatory protein 1-Î± MNA Microneedle array"/>
  <result pre="coronavirus MIP1A Macrophage inflammatory protein 1-Î± MNA Microneedle array MyD88" exact="Myeloid" post="differentiation primary response gene 88 NAD Nicotinamide adenine dinucleotide"/>
  <result pre="Macrophage inflammatory protein 1-Î± MNA Microneedle array MyD88 Myeloid differentiation" exact="primary" post="response gene 88 NAD Nicotinamide adenine dinucleotide NP Nucleocapsid"/>
  <result pre="RNA dependent RNA polymerase S Spike SAHA Suberanilohydroxamic acid SARS-CoV" exact="Severe" post="acute respiratory syndrome coronavirus sHLH Secondary haemophagocytic lymphohistiocytosis SIRT1"/>
  <result pre="dependent RNA polymerase S Spike SAHA Suberanilohydroxamic acid SARS-CoV Severe" exact="acute" post="respiratory syndrome coronavirus sHLH Secondary haemophagocytic lymphohistiocytosis SIRT1 Silent"/>
  <result pre="RNA polymerase S Spike SAHA Suberanilohydroxamic acid SARS-CoV Severe acute" exact="respiratory" post="syndrome coronavirus sHLH Secondary haemophagocytic lymphohistiocytosis SIRT1 Silent information"/>
  <result pre="polymerase S Spike SAHA Suberanilohydroxamic acid SARS-CoV Severe acute respiratory" exact="syndrome" post="coronavirus sHLH Secondary haemophagocytic lymphohistiocytosis SIRT1 Silent information regulator"/>
  <result pre="SAHA Suberanilohydroxamic acid SARS-CoV Severe acute respiratory syndrome coronavirus sHLH" exact="Secondary" post="haemophagocytic lymphohistiocytosis SIRT1 Silent information regulator T1 SOCS1 Suppressor"/>
  <result pre="transducer and activator of transcription 1 TLRs Toll-like receptors TNF" exact="Tumor" post="necrosis factor TNFR Tumor necrosis factor receptor TRIF TIR-domain-containing"/>
  <result pre="transcription 1 TLRs Toll-like receptors TNF Tumor necrosis factor TNFR" exact="Tumor" post="necrosis factor receptor TRIF TIR-domain-containing adapter-inducing interferon-Î² TRMT1 tRNA"/>
  <result pre="for virus origins and receptor bindingThe Lancet.2020395565574 4.DyallJGrossRKindrachukJJohnsonRFOlingerGGHensleyLEet al.Middle East" exact="respiratory" post="syndrome and severe acute respiratory syndrome: current therapeutic options"/>
  <result pre="virus origins and receptor bindingThe Lancet.2020395565574 4.DyallJGrossRKindrachukJJohnsonRFOlingerGGHensleyLEet al.Middle East respiratory" exact="syndrome" post="and severe acute respiratory syndrome: current therapeutic options and"/>
  <result pre="receptor bindingThe Lancet.2020395565574 4.DyallJGrossRKindrachukJJohnsonRFOlingerGGHensleyLEet al.Middle East respiratory syndrome and severe" exact="acute" post="respiratory syndrome: current therapeutic options and potential targets for"/>
  <result pre="bindingThe Lancet.2020395565574 4.DyallJGrossRKindrachukJJohnsonRFOlingerGGHensleyLEet al.Middle East respiratory syndrome and severe acute" exact="respiratory" post="syndrome: current therapeutic options and potential targets for novel"/>
  <result pre="5.ZakiAMVan BoheemenSBestebroerTMOsterhausADMEFouchierRAMIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med.20123671814182023075143 6.LauSKPFanRYYLukHKHZhuLFungJLiKSMet al.Replication of"/>
  <result pre="originsEmerg Microbes Infect.2018720930531999 7.JossetLMenacheryVDGralinskiLEAgnihothramSSovaPCarter VS, et alCell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
  <result pre="important differences with SARS coronavirus. mBio.20134e00165e0011323631916 8.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.Asymptomatic carrier state," exact="acute" post="respiratory disease, and pneumonia due to severe acute respiratory"/>
  <result pre="differences with SARS coronavirus. mBio.20134e00165e0011323631916 8.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.Asymptomatic carrier state, acute" exact="respiratory" post="disease, and pneumonia due to severe acute respiratory syndrome"/>
  <result pre="coronavirus. mBio.20134e00165e0011323631916 8.LaiCCLiuYHWangCYWangYHHsuehSCYenMYet al.Asymptomatic carrier state, acute respiratory disease, and" exact="pneumonia" post="due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2):"/>
  <result pre="carrier state, acute respiratory disease, and pneumonia due to severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol"/>
  <result pre="state, acute respiratory disease, and pneumonia due to severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol Immunol"/>
  <result pre="acute respiratory disease, and pneumonia due to severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2): Facts and mythsJ Microbiol Immunol Infect.20205340441232173241"/>
  <result pre="and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV" exact="infection" post="in Vero E6 cellsBiochim Biophys Acta - Mol Basis"/>
  <result pre="what lessons have we learned? Int J Epidemiol. 2020:1â€&quot;10. 13.LaiCCShihTPKoWCTangHJHsuehPRSevere" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19):"/>
  <result pre="lessons have we learned? Int J Epidemiol. 2020:1â€&quot;10. 13.LaiCCShihTPKoWCTangHJHsuehPRSevere acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The"/>
  <result pre="have we learned? Int J Epidemiol. 2020:1â€&quot;10. 13.LaiCCShihTPKoWCTangHJHsuehPRSevere acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic"/>
  <result pre="landscapeProc Natl Acad Sci.2018115E1012E102129339515 18.SchÃ¤ferABaricRSEpigenetic landscape during coronavirus infectionPathogens.201768 19.AstutiIYsrafil." exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of"/>
  <result pre="Natl Acad Sci.2018115E1012E102129339515 18.SchÃ¤ferABaricRSEpigenetic landscape during coronavirus infectionPathogens.201768 19.AstutiIYsrafil. Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral"/>
  <result pre="Acad Sci.2018115E1012E102129339515 18.SchÃ¤ferABaricRSEpigenetic landscape during coronavirus infectionPathogens.201768 19.AstutiIYsrafil. Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure"/>
  <result pre="Sci.2018115E1012E102129339515 18.SchÃ¤ferABaricRSEpigenetic landscape during coronavirus infectionPathogens.201768 19.AstutiIYsrafil. Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2): An overview of viral structure and"/>
  <result pre="Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of" exact="viral" post="structure and host responseDiabetes Metab Syndr Clin Res Rev.202014407412"/>
  <result pre="a perspective. endocr metab immune disord - DrugTargets.202020807811 26.Dâ€™OnofrioNVitielloMCasaleRServilloLGiovaneABalestrieriMLSirtuins in" exact="vascular" post="diseases: Emerging roles and therapeutic potentialBiochim Biophys Acta BBA"/>
  <result pre="- Mol Basis Dis.1852201513111322 27.YacoubRLeeKHeJCThe Role of SIRT1 in Diabetic" exact="Kidney" post="DiseaseFront Endocrinol.20145166 28.KimENKimMYLimJHKimYShinSJParkCWet al.The protective effect of resveratrol on"/>
  <result pre="Kidney DiseaseFront Endocrinol.20145166 28.KimENKimMYLimJHKimYShinSJParkCWet al.The protective effect of resveratrol on" exact="vascular" post="aging by modulation of the reninâ€&quot;angiotensin systemAtherosclerosis.201827012313129407880 29.ChengHWangYWangGOrgan-protective effect"/>
  <result pre="prognosis of COVID-19J Med Virol.20209272673032221983 30.VerdecchiaPCavalliniCSpanevelloAAngeliFThe pivotal link between ACE2" exact="deficiency" post="and SARS-CoV-2 infectionEur J Intern Med.202076142032336612 31.DevauxCARolainJ-MRaoultDACE2 receptor polymorphism:"/>
  <result pre="deficiency and SARS-CoV-2 infectionEur J Intern Med.202076142032336612 31.DevauxCARolainJ-MRaoultDACE2 receptor polymorphism:" exact="Susceptibility to" post="SARS- CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcomeJ"/>
  <result pre="polymorphism: Susceptibility to SARS- CoV-2, hypertension, multi-organ failure, and COVID-19" exact="disease" post="outcomeJ Microbiol Immunol Infect.20205342543532414646 32.WentworthDETresnanDBTurnerBCLermanIRBullisBHemmilaEMet al.Cells of human aminopeptidase"/>
  <result pre="N-Linked GlycosylationJ Virol.2001759741975211559807 34.WulfÃ¤ngerJSchneiderHWildPIkenbergKRodolfoMRivoltiniLet al.Promoter methylation of aminopeptidase N/CD13 in" exact="malignant" post="melanomaCarcinogenesis.20123378179022307972 35.SmithEMZhangLWalkerBADavenportELAronsonLIKrigeDet al.The combination of HDAC and aminopeptidase inhibitors"/>
  <result pre="combination of HDAC and aminopeptidase inhibitors is highly synergistic in" exact="myeloma" post="and leads to disruption of the NFÎºB signalling pathwayOncotarget.20156173141732726015393"/>
  <result pre="transcriptionally up-regulating the exopeptidase DPP4J Biol Chem.20202953213322731988243 37.SubissiLPosthumaCCColletAZevenhoven-DobbeJCGorbalenyaAEDecrolyEet al.One severe" exact="acute" post="respiratory syndrome coronavirus protein complex integrates processive RNA polymerase"/>
  <result pre="up-regulating the exopeptidase DPP4J Biol Chem.20202953213322731988243 37.SubissiLPosthumaCCColletAZevenhoven-DobbeJCGorbalenyaAEDecrolyEet al.One severe acute" exact="respiratory" post="syndrome coronavirus protein complex integrates processive RNA polymerase and"/>
  <result pre="the exopeptidase DPP4J Biol Chem.20202953213322731988243 37.SubissiLPosthumaCCColletAZevenhoven-DobbeJCGorbalenyaAEDecrolyEet al.One severe acute respiratory" exact="syndrome" post="coronavirus protein complex integrates processive RNA polymerase and exonuclease"/>
  <result pre="Acad Sci.2014111E3900E390925197083 38.ZaborowskaJIsaNFMurphySP-TEFb goes viral: The role of P-TEFb in" exact="viral" post="infectionBioEssays.201638S75S8527417125 39.Ait-AmmarAKulaADarcisGVerdiktRDe WitSGautierVet al.Current status of latency reversing agents"/>
  <result pre="S A.20061035108511316549795 41.BudayevaHGRowlandEACristeaIMIntricate Roles of Mammalian Sirtuins in Defense against" exact="Viral" post="PathogensJ Virol.2016905826491165 42.KalbasDLiebscherSNowakTMeleshinMPannekMPoppCet al.Potent and Selective Inhibitors of Human"/>
  <result pre="Sirtuins in Defense against Viral PathogensJ Virol.2016905826491165 42.KalbasDLiebscherSNowakTMeleshinMPannekMPoppCet al.Potent and" exact="Selective" post="Inhibitors of Human Sirtuin 5J Med Chem.2018612460247129494161 43.GuBLiuCLin-GoerkeJMaleyDRGutshallLLFeltenbergerCAet al.The"/>
  <result pre="al.The RNA helicase and nucleotide triphosphatase activities of the bovine" exact="viral" post="diarrhea virus NS3 protein are essential for viral replicationJ"/>
  <result pre="RNA helicase and nucleotide triphosphatase activities of the bovine viral" exact="diarrhea" post="virus NS3 protein are essential for viral replicationJ Virol.2000741794180010644352"/>
  <result pre="the bovine viral diarrhea virus NS3 protein are essential for" exact="viral" post="replicationJ Virol.2000741794180010644352 44.LiXYangHHuangSQiuYHistone deacetylase 1 and p300 can directly"/>
  <result pre="targets for drug repurposing. Nature. Available at: http://www.nature.com/articles/s41586-020-2286-9 (2020). 46.FerronFDecrolyESeliskoBCanardBThe" exact="viral" post="RNA capping machinery as a target for antiviral drugsAntiviral"/>
  <result pre="and oxidative stress survivalMol Cell Biol.201737e00214e0021728784718 51.LinSCHoCTChuoWHLiSWangTTLinCCEffective inhibition of MERS-CoV" exact="infection" post="by resveratrolBMC Infect Dis.20171714428193191 52.Taiaroa G, Rawlinson D, Featherstone"/>
  <result pre="the treatment of SARS: Initial virological and clinical findingsThorax.20045925225614985565 54.PeirisJSMYuenKYOsterhausADMEStÃ¶hrKThe" exact="Severe" post="Acute Respiratory SyndromeN Engl J Med.20033492431244114681510 55.AdhikariSPMengSWuYJMaoYPYeRXWangQZet al.Epidemiology, causes,"/>
  <result pre="treatment of SARS: Initial virological and clinical findingsThorax.20045925225614985565 54.PeirisJSMYuenKYOsterhausADMEStÃ¶hrKThe Severe" exact="Acute" post="Respiratory SyndromeN Engl J Med.20033492431244114681510 55.AdhikariSPMengSWuYJMaoYPYeRXWangQZet al.Epidemiology, causes, clinical"/>
  <result pre="of SARS: Initial virological and clinical findingsThorax.20045925225614985565 54.PeirisJSMYuenKYOsterhausADMEStÃ¶hrKThe Severe Acute" exact="Respiratory" post="SyndromeN Engl J Med.20033492431244114681510 55.AdhikariSPMengSWuYJMaoYPYeRXWangQZet al.Epidemiology, causes, clinical manifestation"/>
  <result pre="causes, clinical manifestation and diagnosis, prevention and control of coronavirus" exact="disease" post="(COVID-19) during the early outbreak period: A scoping reviewInfect"/>
  <result pre="the early outbreak period: A scoping reviewInfect Dis Poverty.202092932183901 56.ChengVCCLauSKPWooPCYKwokYYSevere" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
  <result pre="early outbreak period: A scoping reviewInfect Dis Poverty.202092932183901 56.ChengVCCLauSKPWooPCYKwokYYSevere acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
  <result pre="outbreak period: A scoping reviewInfect Dis Poverty.202092932183901 56.ChengVCCLauSKPWooPCYKwokYYSevere acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infectionClin"/>
  <result pre="infectionClin Microbiol Rev.20072066069417934078 57.KoyuncuEBudayevaHGMitevaYVRicciDPSilhavyTJShenk T, et alSirtuins are evolutionarily conserved" exact="viral" post="restriction factors. mBio.20145e02249e0221425516616 58.PatnaikSAnupriyaDrugs targeting epigenetic modifications and plausible"/>
  <result pre="mBio.20145e02249e0221425516616 58.PatnaikSAnupriyaDrugs targeting epigenetic modifications and plausible therapeutic strategies against" exact="colorectal cancer." post="Front Pharmacol.20191058831244652 59.DejligbjergMGrauslundMLitmanTCollinsLQianXJeffersMet al.Differential effects of class I isoform"/>
  <result pre="by histone acetylation in macrophages and its role in paraquat-induced" exact="pulmonary" post="fibrosisFront Immunol.2017769628194150 61.DekkerFJVan Den BoschTMartinNISmall molecule inhibitors of histone"/>
  <result pre="mechanisms for the regulation of IL-10Semin Immunol.20194410132431676122 64.HerbeinGWendlingDHistone deacetylases in" exact="viral" post="infectionsClin Epigenetics.20101132422704086 65.Zwergel C, Stazi G, Valente S, Mai"/>
  <result pre="IL13 promoters in CD4 + T cells of patients with" exact="systemic" post="lupus erythematosusJ Biomed Biotechnol.2010201019 68.NehmeZPasquereauSHerbeinGControl of viral infections by"/>
  <result pre="promoters in CD4 + T cells of patients with systemic" exact="lupus" post="erythematosusJ Biomed Biotechnol.2010201019 68.NehmeZPasquereauSHerbeinGControl of viral infections by epigenetic-targeted"/>
  <result pre="of patients with systemic lupus erythematosusJ Biomed Biotechnol.2010201019 68.NehmeZPasquereauSHerbeinGControl of" exact="viral" post="infections by epigenetic-targeted therapyClin Epigenetics.2019115530917875 69.LarssonLThorbert-MrosSRymoLBerglundhTInfluence of epigenetic modifications"/>
  <result pre="patients with systemic lupus erythematosusJ Biomed Biotechnol.2010201019 68.NehmeZPasquereauSHerbeinGControl of viral" exact="infections" post="by epigenetic-targeted therapyClin Epigenetics.2019115530917875 69.LarssonLThorbert-MrosSRymoLBerglundhTInfluence of epigenetic modifications of"/>
  <result pre="Sci.2012120142022288916 70.IyerSSChengGRole of interleukin 10 transcriptional regulation in inflammation and" exact="autoimmune" post="diseaseCrit Rev Immunol.201232236322428854 71.ColeJMorrisPDickmanMJDockrellDHThe therapeutic potential of epigenetic manipulation"/>
  <result pre="diseaseCrit Rev Immunol.201232236322428854 71.ColeJMorrisPDickmanMJDockrellDHThe therapeutic potential of epigenetic manipulation during" exact="infectious" post="diseasesPharmacol Ther.2016167859927519803 72.KepplerBRArcherTKChromatin-modifying enzymes as therapeutic targets â€&quot; Part"/>
  <result pre="differentiation and shows synergistic cytotoxicity with other epigenetic drugs in" exact="acute" post="myeloid leukemia cellsBlood Cancer J.20155e31325978433 74.WangJLiGLMingSLWangCFShiLJSuBQet al.BRD4 inhibition exerts"/>
  <result pre="and shows synergistic cytotoxicity with other epigenetic drugs in acute" exact="myeloid leukemia" post="cellsBlood Cancer J.20155e31325978433 74.WangJLiGLMingSLWangCFShiLJSuBQet al.BRD4 inhibition exerts anti-viral activity"/>
  <result pre="shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid" exact="leukemia" post="cellsBlood Cancer J.20155e31325978433 74.WangJLiGLMingSLWangCFShiLJSuBQet al.BRD4 inhibition exerts anti-viral activity"/>
  <result pre="cytotoxicity with other epigenetic drugs in acute myeloid leukemia cellsBlood" exact="Cancer" post="J.20155e31325978433 74.WangJLiGLMingSLWangCFShiLJSuBQet al.BRD4 inhibition exerts anti-viral activity through DNA"/>
  <result pre="of cytokine storm and immunopathologySemin Immunopathol.20173952953928466096 79.WalshKBTeijaroJRBrockLGFremgenDMCollinsPLRosenHet al.Animal model of" exact="respiratory" post="syncytial virus: CD8+ T cells cause a cytokine storm"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): The Perspectives of clinical immunologists from ChinaClin"/>
  <result pre="Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2" exact="viral" post="load (RNAaemia) is closely associated with drastically elevated interleukin"/>
  <result pre="interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in" exact="lupus" post="patientsClin Immunol.202021510841032276140 84.LedfordHCoronavirus breakthrough: dexamethasone is first drug shown"/>
  <result pre="Inflamm.2015201518 91.YangFZhouSWangCHuangYLiHWangYet al.Epigenetic modifications of interleukin-6 in synovial fibroblasts from" exact="osteoarthritis" post="patientsSci Rep.201774359228262826 92.ChenSYangJWeiYWeiXEpigenetic regulation of macrophages: from homeostasis maintenance"/>
  <result pre="by DNA methylation in obesityJCI Insight.20161e8774827882346 94.Thomas G. Middle East" exact="respiratory" post="syndrome coronavirus Joint Kingdom of Saudi Arabia/WHO mission. WHO."/>
  <result pre="DNA methylation in obesityJCI Insight.20161e8774827882346 94.Thomas G. Middle East respiratory" exact="syndrome" post="coronavirus Joint Kingdom of Saudi Arabia/WHO mission. WHO. 2013;"/>
  <result pre="in obesityJCI Insight.20161e8774827882346 94.Thomas G. Middle East respiratory syndrome coronavirus" exact="Joint" post="Kingdom of Saudi Arabia/WHO mission. WHO. 2013; https://www.who.int/mediacentre/news/releases/2013/mers_cov_20130610/en/. ."/>
  <result pre="WHO. 2013; https://www.who.int/mediacentre/news/releases/2013/mers_cov_20130610/en/. . 95.RothanHAByrareddySNThe epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ Autoimmun.202010910243332113704 96.Principi N, Esposito S. Chloroquine or"/>
 </snippets>
</snippetsTree>
